Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 2Phase 2/3 1

Status

Recruiting 3Active not recruiting 2Completed 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Gastrointestinal 28Thoracic 26Head & Neck 9Dermatologic 6Tumor-Agnostic 5Genitourinary 5Breast 5Gynecologic 4CNS 3Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1

Conditions

Melanoma 6Carcinoma, Non-Small-Cell Lung 2Neoplasm Metastasis 1Gastrointestinal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 156Nivolumab 131Ipilimumab 76Cyclophosphamide 46Specimen Handling 44Magnetic Resonance Spectroscopy 39cemiplimab 35Biopsy 31fludarabine 28trametinib 24relatlimab 24binimetinib 23Interleukin-2 21fludarabine phosphate 20dabrafenib 20atezolizumab 20Radiotherapy 19Opdualag 19Radiosurgery 18encorafenib 17aldesleukin 17CTLA-4 Antigen 17Blood Specimen Collection 17avelumab 14Immunoglobulin G 14Disulfides 13lenvatinib 11Bevacizumab 11lifileucel 10Paclitaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Immunotherapy × Dermatologic × 1 year × Clear all
NCT02645149 2026-05-29

Match Mel

Melanoma Institute Australia

Phase 2 Completed
216 enrolled
Dermatologic

Melanoma

NCT06624644 2026-04-22

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Linnaeus Therapeutics, Inc.

Phase 2/3 Recruiting
135 enrolled
Dermatologic

Melanoma

NCT04594187 2026-02-17

MelPORT

M.D. Anderson Cancer Center

Phase 2 Recruiting
168 enrolled
Dermatologic

Melanoma

NCT07407166 2026-02-17

Efficacy of First-Line Immunotherapy in Metastatic Melanoma in Slovenia and Identification of Predictive Biomarkers

Institute of Oncology Ljubljana

Phase NA Recruiting
40 enrolled
Dermatologic

Melanoma

NCT05863052 2026-02-10

Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population

University of Oklahoma

Active not recruiting
72 enrolled
DermatologicGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Gastrointestinal Neoplasms, Melanoma, Neoplasm Metastasis

NCT06146920 2025-11-18

Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation

Massachusetts General Hospital

Phase NA Active not recruiting
39 enrolled
DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡